Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Phc Corporation currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, suggesting that the company's active filings cover at least 2 different technical niches within the broader biotech sector. This distribution requires the company to navigate the specific examination standards of multiple units simultaneously.
The prosecution workload is handled by 3 distinct examiners, which means each of the 3 pending office actions is assigned to a different individual. GIERE, REBECCA M is the busiest examiner for the portfolio, though she is responsible for only 1 busiest examiner pending action. This indicates that the workload is spread, with no single examiner holding a majority of the pending cases.
The presence of 3 distinct examiners for 3 pending office actions across 2 distinct art units highlights a decentralized prosecution environment. Practitioners must manage separate examiner relationships while addressing the technical requirements of the Biotechnology & Pharmaceuticals field. The data shows that Phc Corporation's current patent office interactions are fragmented rather than concentrated under a single examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GIERE, REBECCA M | 1 | 73.7% | +32.3% |
| DUNN, MCKENZIE A | 1 | 53.8% | +56.3% |
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261155 | METHOD FOR PREDICTING RISK FOR THROMBOSIS IN CANCER PATIENT USING SOLUBLE CLEC2 | REDDIG, PETER J | 15d overdue |
| 18713773 | METHOD FOR MEASURING ELASTASE 1 IN FECES | GIERE, REBECCA M | — |
| 18575425 | BIOMARKER FOR DETECTING TUBULOINTERSTITIAL DISORDER AND USE THEREOF | DUNN, MCKENZIE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261155 | METHOD FOR PREDICTING RISK FOR THROMBOSIS IN CANCER PATIENT USING SOLUBLE CLEC2 | REDDIG, PETER J | 15d overdue |
| 18713773 | METHOD FOR MEASURING ELASTASE 1 IN FECES | GIERE, REBECCA M | — |
| 18575425 | BIOMARKER FOR DETECTING TUBULOINTERSTITIAL DISORDER AND USE THEREOF | DUNN, MCKENZIE A | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713773 | METHOD FOR MEASURING ELASTASE 1 IN FECES | GIERE, REBECCA M | — | §102§103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18575425 | BIOMARKER FOR DETECTING TUBULOINTERSTITIAL DISORDER AND USE THEREOF | DUNN, MCKENZIE A | — | §103§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18261155 | METHOD FOR PREDICTING RISK FOR THROMBOSIS IN CANCER PATIENT USING SOLUBLE CLEC2 | REDDIG, PETER J | 1646 | §101§112 | Final Rejection | 15d overdue | Pending | Jul 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial